BioAge Labs (BIOA) Equity Average (2023 - 2026)

BioAge Labs has disclosed Equity Average across 4 years of filings, most recently posting $325.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $325.6 million, up 2.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $325.6 million (up 2.34% YoY), and the FY2025 annual result was $297.6 million, up 297.5% from the prior year.
• Equity Average came in at $325.6 million for Q1 2026 at BioAge Labs, up from $274.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $325.6 million in Q1 2026 to a low of -$191.3 million in Q2 2024.
• The 4-year median for Equity Average is $280.4 million (2025), against an average of $135.1 million.
• Peak annual rise in Equity Average reached 390.7% in 2025, while the deepest fall reached 13.72% in 2025.
• BioAge Labs' Equity Average stood at -$163.3 million in 2023, then jumped by 295.04% to $318.4 million in 2024, then fell by 13.72% to $274.8 million in 2025, then increased by 18.5% to $325.6 million in 2026.
• The last three Equity Average figures came in at $325.6 million (Q1 2026), $274.8 million (Q4 2025), and $286.1 million (Q3 2025), per Business Quant data.